These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 6500733)

  • 1. Heparin for hemodialysis: practical guidelines for administration and monitoring.
    Mingardi G; Perico N; Pusineri F; Massazza M; Marchesi E; Mecca G; Remuzzi G; Donati MB
    Int J Artif Organs; 1984 Sep; 7(5):269-74. PubMed ID: 6500733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The conflict between anticoagulation and hemostasis during hemodialysis.
    Vogel GE; Kopp KF
    Int J Artif Organs; 1978 Jul; 1(4):181-6. PubMed ID: 669842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical use of a totally heparin grafted hemodialysis system in uremic patients.
    Schmer G; Teng LN; Vizzo JE; Graefe U; Milutinovich J; Cole JJ; Scribner BH
    Trans Am Soc Artif Intern Organs; 1977; 23():177-84. PubMed ID: 910332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison between tinzaparin and standard heparin for chronic hemodialysis in a Canadian center.
    Lord H; Jean N; Dumont M; Kassis J; Leblanc M
    Am J Nephrol; 2002; 22(1):58-66. PubMed ID: 11919404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of vitamin-E-modified dialysers on dialyser clotting, erythropoietin and heparin dosage: a comparative crossover study.
    Huraib S; Tanimu D; Shaheen F; Hejaili F; Giles C; Pagayon V
    Am J Nephrol; 2000; 20(5):364-8. PubMed ID: 11092992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of coagulation and anti-Xa factor when using a heparin-coated AN69ST® dialyser.
    Sánchez-Canel JJ; Pons-Prades R; Salvetti ML; Seores A; Vázquez M; Pérez-Alba A; Tamarit E; Calvo-Gordo C; Villatoro J
    Nefrologia; 2012; 32(5):605-12. PubMed ID: 23013946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prevention of thrombogenesis in the extracorporeal circuit of hemodialysis with a low molecular heparin: standardization of the dosage with a better hemorrhagic risk/effectiveness ratio].
    Barata JD; Oliveira C; Bruges M; Gusmão L; Santana A; Ponce P; Simões J; Freire I; Crespo F; da Silva AN
    Acta Med Port; 1992 Feb; 5(2):65-70. PubMed ID: 1317657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activated clotting time during cardiopulmonary bypass: is repetition necessary during open heart surgery?
    Neema PK; Sinha PK; Rathod RC
    Asian Cardiovasc Thorac Ann; 2004 Mar; 12(1):47-52. PubMed ID: 14977742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inactivation of heparin during extracorporeal circulation in infants.
    Green TP; Isham-Schopf B; Irmiter RJ; Smith C; Uden DL; Steinhorn RH
    Clin Pharmacol Ther; 1990 Aug; 48(2):148-54. PubMed ID: 2379386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activated partial thromboplastin time is a better trending tool in pediatric extracorporeal membrane oxygenation.
    Maul TM; Wolff EL; Kuch BA; Rosendorff A; Morell VO; Wearden PD
    Pediatr Crit Care Med; 2012 Nov; 13(6):e363-71. PubMed ID: 22940857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane.
    Lavaud S; Canivet E; Wuillai A; Maheut H; Randoux C; Bonnet JM; Renaux JL; Chanard J
    Nephrol Dial Transplant; 2003 Oct; 18(10):2097-104. PubMed ID: 13679486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparinization for routine hemodialysis.
    Ward RA
    Adv Ren Replace Ther; 1995 Oct; 2(4):362-70. PubMed ID: 8591127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Kinetics of anticoagulation in hemodialysis. Sequential study of single, intermittent and continuous heparinization].
    Ghezzi PM; Di Siena F; Palanca R; Dutto A; Cento G
    Minerva Med; 1980 Oct; 71(41):2987-91. PubMed ID: 7454084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticoagulation therapy advisor: a decision-support system for heparin therapy during ECMO.
    Peverini RL; Sale M; Rhine WD; Fagan LM; Lenert LA
    Proc Annu Symp Comput Appl Med Care; 1992; ():567-71. PubMed ID: 1482937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation.
    Despotis GJ; Joist JH; Hogue CW; Alsoufiev A; Kater K; Goodnough LT; Santoro SA; Spitznagel E; Rosenblum M; Lappas DG
    J Thorac Cardiovasc Surg; 1995 Jul; 110(1):46-54. PubMed ID: 7609568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A low molecular heparin fraction as an anticoagulant during hemodialysis.
    Ljungberg B
    Clin Nephrol; 1985 Jul; 24(1):15-20. PubMed ID: 4017295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimizing hemorrhagic complications in dialysis patients.
    Lohr JW; Schwab SJ
    J Am Soc Nephrol; 1991 Nov; 2(5):961-75. PubMed ID: 1760540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety of heparins in end-stage renal disease.
    Sonawane S; Kasbekar N; Berns JS
    Semin Dial; 2006; 19(4):305-10. PubMed ID: 16893408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heparin-coated polyacrylonitrile membrane versus regional citrate anticoagulation: a prospective randomized study of 2 anticoagulation strategies in patients at risk of bleeding.
    Evenepoel P; Dejagere T; Verhamme P; Claes K; Kuypers D; Bammens B; Vanrenterghem Y
    Am J Kidney Dis; 2007 May; 49(5):642-9. PubMed ID: 17472846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intermittent heparin treatment does not induce hypercoagulability in haemodialysed patients.
    Pusineri F; Bini A; Mussoni L; Remuzzi G; Donati MB
    J Clin Pathol; 1980 Jul; 33(7):631-4. PubMed ID: 6776154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.